| Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist SI Sayin, A Wahlström, J Felin, S Jäntti, HU Marschall, K Bamberg, ... Cell metabolism 17 (2), 225-235, 2013 | 2155 | 2013 |
| Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism A Wahlström, SI Sayin, HU Marschall, F Bäckhed Cell metabolism 24 (1), 41-50, 2016 | 2128 | 2016 |
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases European Association For The Study Of The Liver Journal of hepatology 51 (2), 237-267, 2009 | 1821 | 2009 |
| Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease O Ringdén, M Uzunel, I Rasmusson, M Remberger, B Sundberg, ... Transplantation 81 (10), 1390-1397, 2006 | 1526 | 2006 |
| Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates A Glantz, HU Marschall, LÅ Mattsson Hepatology 40 (2), 467-474, 2004 | 1163 | 2004 |
| A placebo-controlled trial of obeticholic acid in primary biliary cholangitis F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ... New England Journal of Medicine 375 (7), 631-643, 2016 | 1114 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1081 | 2019 |
| Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ... Gastroenterology 145 (3), 574-582. e1, 2013 | 1049 | 2013 |
| Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci D Ellinghaus, L Jostins, SL Spain, A Cortes, J Bethune, B Han, YR Park, ... Nature genetics 48 (5), 510-518, 2016 | 729 | 2016 |
| Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management F Lammert, HU Marschall, A Glantz, S Matern Journal of hepatology 33 (6), 1012-1021, 2000 | 697 | 2000 |
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ... Gastroenterology 148 (4), 751-761. e8, 2015 | 686 | 2015 |
| Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota J Wang, LB Thingholm, J Skiecevičienė, P Rausch, M Kummen, JR Hov, ... Nature genetics 48 (11), 1396-1406, 2016 | 617 | 2016 |
| Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice P Fickert, A Fuchsbichler, M Wagner, G Zollner, A Kaser, H Tilg, R Krause, ... Gastroenterology 127 (1), 261-274, 2004 | 552 | 2004 |
| Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses C Ovadia, PT Seed, A Sklavounos, V Geenes, C Di Ilio, J Chambers, ... The Lancet 393 (10174), 899-909, 2019 | 486 | 2019 |
| Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ... Gastroenterology 152 (8), 1975-1984. e8, 2017 | 481 | 2017 |
| High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study R Olsson, KM Boberg, OS de Muckadell, S Lindgren, R Hultcrantz, ... Gastroenterology 129 (5), 1464-1472, 2005 | 465 | 2005 |
| Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ... Nature genetics 45 (6), 670-675, 2013 | 433 | 2013 |
| Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations G Zollner, HU Marschall, M Wagner, M Trauner Molecular pharmaceutics 3 (3), 231-251, 2006 | 430 | 2006 |
| Whole-genome Sequencing of Patients With Rare Diseases in a National Health System OWH NIHR BioResource for the 100,000 Genomes Project, Kingston N, Walker N ... Nature 583, 96-102, 2020 | 407 | 2020 |
| CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice M Wagner, E Halilbasic, HU Marschall, G Zollner, P Fickert, C Langner, ... Hepatology 42 (2), 420-430, 2005 | 403 | 2005 |
peter fickertProfessor of Medicine在 medunigraz.at 的电子邮件经过验证
